These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25642418)

  • 1. Regulation of PP2A by Sphingolipid Metabolism and Signaling.
    Oaks J; Ogretmen B
    Front Oncol; 2014; 4():388. PubMed ID: 25642418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
    De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
    FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide in the prostate.
    Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.
    Mukhopadhyay A; Saddoughi SA; Song P; Sultan I; Ponnusamy S; Senkal CE; Snook CF; Arnold HK; Sears RC; Hannun YA; Ogretmen B
    FASEB J; 2009 Mar; 23(3):751-63. PubMed ID: 19028839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The repression of oncoprotein SET by the tumor suppressor p53 reveals a p53-SET-PP2A feedback loop for cancer therapy.
    Yao H; Xu W; Liu Y; Cao Z; Wen J; Zhang M; Wu Z; Yan X; Jiao Z; Zhang Z; Chen J; Zhang M; Zhu WG; Wang D
    Sci China Life Sci; 2023 Jan; 66(1):81-93. PubMed ID: 35881220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia.
    Ramaswamy K; Spitzer B; Kentsis A
    Front Oncol; 2015; 5():16. PubMed ID: 25699237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.
    Kauko O; Westermarck J
    Int J Biochem Cell Biol; 2018 Mar; 96():157-164. PubMed ID: 29355757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
    Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
    Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.
    Perrotti D; Neviani P
    Cancer Metastasis Rev; 2008 Jun; 27(2):159-68. PubMed ID: 18213449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
    Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
    J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal ceroid lipofuscinosis related ER membrane protein CLN8 regulates PP2A activity and ceramide levels.
    Adhikari B; De Silva B; Molina JA; Allen A; Peck SH; Lee SY
    Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):322-328. PubMed ID: 30453012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.
    Arriazu E; Pippa R; Odero MD
    Front Oncol; 2016; 6():78. PubMed ID: 27092295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth.
    Williams AP; Garner EF; Waters AM; Stafman LL; Aye JM; Markert H; Stewart JE; Beierle EA
    Transl Oncol; 2019 Jan; 12(1):84-95. PubMed ID: 30286326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of PP2A.
    O'Connor CM; Perl A; Leonard D; Sangodkar J; Narla G
    Int J Biochem Cell Biol; 2018 Mar; 96():182-193. PubMed ID: 29107183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PP2A-Mediated Anticancer Therapy.
    Chen W; Wang Z; Jiang C; Ding Y
    Gastroenterol Res Pract; 2013; 2013():675429. PubMed ID: 24307892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer.
    Thompson JJ; Williams CS
    Genes (Basel); 2018 Feb; 9(3):. PubMed ID: 29495399
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Roth BM; DePalma RM; Cook ME; Varney KM; Weber DJ; Ogretmen B
    Biomol NMR Assign; 2021 Oct; 15(2):383-387. PubMed ID: 34156643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.